Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 1,854,604 shares, a growth of 445.6% from the May 31st total of 339,948 shares. Based on an average daily trading volume, of 64,500,748 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Stock Performance
OTCMKTS RGBP remained flat at $0.00 during trading hours on Friday. The company had a trading volume of 1,200,884 shares, compared to its average volume of 12,404,889. Regen BioPharma has a 52-week low of $0.00 and a 52-week high of $0.12.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies.
Featured Articles
- Five stocks we like better than Regen BioPharma
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
- Data Center Delays Create Opportunity in These 3 Stocks
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
